Published in Nat Commun on December 23, 2014
IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet (2017) 1.41
Guarding the frontiers: the biology of type III interferons. Nat Immunol (2015) 1.12
Spontaneous Clearance of the Hepatitis C Virus Among Men Who Have Sex With Men. Clin Infect Dis (2015) 0.88
Transcriptome analysis reveals a classical interferon signature induced by IFNλ4 in human primary cells. Genes Immun (2015) 0.86
Expression of Interferon Lambda 4 Is Associated with Reduced Proliferation and Increased Cell Death in Human Hepatic Cells. J Interferon Cytokine Res (2015) 0.86
Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol (2016) 0.86
Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am (2015) 0.77
Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. Sci Rep (2015) 0.77
Innate and Adaptive Immune Responses in Chronic HCV infection. Curr Drug Targets (2015) 0.77
Interferon lambda 4 expression is suppressed by the host during viral infection. J Exp Med (2016) 0.76
Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth. Oncotarget (2016) 0.76
Beyond autophagy: New roles for ULK1 in immune signaling and interferon responses. Cytokine Growth Factor Rev (2016) 0.76
High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease. J Hepatol (2016) 0.76
Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types. J Mol Diagn (2015) 0.75
Interferon Lambda: Modulating Immunity in Infectious Diseases. Front Immunol (2017) 0.75
IFN-λ3 polymorphism indirectly influences NK cell phenotype and function during acute HCV infection. Immun Inflamm Dis (2016) 0.75
IFN-λ4 potently blocks IFN-α signalling by ISG15 and USP18 in hepatitis C virus infection. Sci Rep (2017) 0.75
Type III Interferons in Hepatitis C Virus Infection. Front Immunol (2016) 0.75
Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat Genet (2017) 0.75
Contribution of Type III Interferons to Antiviral Immunity; Location, Location, Location. J Biol Chem (2017) 0.75
The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy. J Immunol Res (2017) 0.75
IFN-λ4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling. J Immunol (2017) 0.75
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A (2008) 8.56
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology (2005) 5.33
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology (2010) 2.68
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun (2008) 2.40
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med (2013) 2.24
Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem (2009) 1.73
Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol (2009) 1.61
USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response. PLoS One (2011) 1.60
Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J (2013) 1.40
IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis (2013) 1.39
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol (2013) 1.35
Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol (2007) 1.28
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med (2011) 1.19
Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. J Infect Dis (2013) 1.18
Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? J Viral Hepat (2012) 1.17
Acute hepatitis C: current status and remaining challenges. J Hepatol (2008) 1.13
Crystal structure of human interferon-λ1 in complex with its high-affinity receptor interferon-λR1. J Mol Biol (2010) 1.09
Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha. J Med Virol (2006) 1.03
Lymphocytes degranulation in liver in hepatitis C virus carriers is associated with IFNL4 polymorphisms and ALT levels. J Infect Dis (2014) 0.88
IL28B in the era of direct-acting antivirals for hepatitis C. J Clin Gastroenterol (2013) 0.86
The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS (2014) 0.86
Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? Antivir Ther (2012) 0.80
Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients. J Clin Virol (2014) 0.79
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol (2009) 3.28
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (2011) 2.11
A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clin Sci (Lond) (2011) 1.59
Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol (2007) 1.28
Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol (2011) 1.19
Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver Int (2011) 1.10
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology (2012) 1.09
A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One (2012) 1.05
Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PLoS One (2013) 0.97
The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. Antivir Ther (2011) 0.93
Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liver Int (2007) 0.92
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology (2012) 0.90
Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. J Hepatol (2013) 0.87
Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients. Liver Int (2013) 0.86
The role of bile acid retention and a common polymorphism in the ABCB11 gene as host factors affecting antiviral treatment response in chronic hepatitis C. J Viral Hepat (2010) 0.84
Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study. J Viral Hepat (2009) 0.78
Birth year distribution in reported hepatitis C cases in Switzerland. Eur J Public Health (2014) 0.76
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology (2016) 0.76
Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection. J Viral Hepat (2012) 0.75
Clinical significance of the CCR5delta32 allele in hepatitis C. PLoS One (2014) 0.75
Corrigendum: reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun (2015) 0.75